Monthly
US$200
Billed every month
Diquafosol Sodium Eye Drops(地夸磷索钠滴眼液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applicationsNo longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders1View records ↓
Under-review filings5View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers63View records ↓
API companies with A status14View records ↓
Chemical-drug catalogue
Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Santen Pharmaceutical Co.,Ltd. | Santen Pharmaceutical Co.,Ltd.Noto Plant | H20181012 | 2017/10/20 | 3%（5ml:150mg） | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 63 distinct approval numbers and 52 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广东南国药业有限公司 | 国药准字H20264803 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010100315 | NHSA |
| 广东众生药业股份有限公司 | 国药准字H20233141 | 3%(5ml∶150mg) | Not stated by source | XS01XAD324G010010100371 | NHSA |
| 深圳市华生元基因工程发展有限公司 | 国药准字H20254149 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010100528 | NHSA |
| 深圳万和制药有限公司 | 国药准字H20243354 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010100547 | NHSA |
| 广州大光制药有限公司 | 国药准字H20255054 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010100548 | NHSA |
| 珠海亿胜生物制药有限公司 | 国药准字H20244650 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010100612 | NHSA |
| 中国大冢制药有限公司 | 国药准字H20255318 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010100967 | NHSA |
| 沈阳兴齐眼药股份有限公司 | 国药准字H20233992 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101322 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20255901 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101438 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20243334 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101503 | NHSA |
| 苏州乐珠制药有限公司 | 国药准字H20249361 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101652 | NHSA |
| 扬子江药业集团有限公司 | 国药准字H20223580 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101749 | NHSA |
| 江苏恒新药业有限公司 | 国药准字H20244672 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101765 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20243571 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101967 | NHSA |
| 武汉五景药业有限公司 | 国药准字H20253766 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101978 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20255135 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010102087 | NHSA |
| 成都普什制药有限公司 | 国药准字H20243167 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010102298 | NHSA |
| 陕西博森生物制药股份集团有限公司 | 国药准字H20244361 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010102357 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20253908 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010102733 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010103094 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20223344 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010104021 | NHSA |
| 山东海山药业有限公司 | 国药准字H20254031 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104094 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20243358 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104127 | NHSA |
| 杭州国光药业股份有限公司 | 国药准字H20243119 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104478 | NHSA |
| 福建博悦医药科技有限公司 | 国药准字H20255222 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104494 | NHSA |
| 浙江尖峰药业有限公司 | 国药准字H20249603 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104655 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20244731 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010104693 | NHSA |
| 珠海前列药业有限公司 | 国药准字H20253203 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104929 | NHSA |
| 江西马应龙美康药业有限公司 | 国药准字H20244360 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010105293 | NHSA |
| 珍视明(江西)药业股份有限公司 | 国药准字H20244250 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010105387 | NHSA |
| 江苏远恒药业有限公司 | 国药准字H20249234 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010106033 | NHSA |
| Santen Pharmaceutical Co., Ltd. | 国药准字J20180008 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010109591 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20244720 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010109920 | NHSA |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ20181012 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010178986 | NHSA |
| 郑州卓峰制药有限公司 | 国药准字H20254146 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010179276 | NHSA |
| 成都盛迪医药有限公司 | 国药准字H20223336 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010180435 | NHSA |
| 山东绅联药业股份有限公司 | 国药准字H20253182 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010180461 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010181567 | NHSA |
| 华润紫竹药业有限公司 | 国药准字H20243438 | 3%(0.4ml∶12mg) | Not stated by source | XS01XAD324G010010183035 | NHSA |
| 北京诺思兰德生物技术股份有限公司 | 国药准字H20234037 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183060 | NHSA |
| 山东博士伦福瑞达制药有限公司 | 国药准字H20255902 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183223 | NHSA |
| 苏州朗科生物技术股份有限公司 | 国药准字H20254814 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183485 | NHSA |
| 苏州欧康维视生物科技有限公司 | 国药准字H20244235 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183562 | NHSA |
| 江苏广承药业有限公司 | 国药准字H20263726 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183611 | NHSA |
| 深圳市宇健生物医药有限公司 | 国药准字H20263224 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183757 | NHSA |
| 黑龙江省知润药业有限公司 | 国药准字H20244800 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183931 | NHSA |
| 武汉先路医药科技股份有限公司 | 国药准字H20255425 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010184190 | NHSA |
| 南京黄龙生物科技有限公司 | 国药准字H20249182 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010184437 | NHSA |
| 南京华兴医药科技有限公司 | 国药准字H20253205 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010184657 | NHSA |
| 润尔眼科药物(广州)有限公司 | 国药准字H20244698 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010184784 | NHSA |
| 郑州维先医药科技有限公司 | 国药准字H20253918 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010185259 | NHSA |
| 佑华医药科技有限公司 | 国药准字H20253859 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010185280 | NHSA |
| 广州大光制药有限公司 | 国药准字H20255054 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010200548 | NHSA |
| 珠海亿胜生物制药有限公司 | 国药准字H20244650 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010200612 | NHSA |
| 成都普什制药有限公司 | 国药准字H20243167 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010202298 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010203094 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20243358 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010204127 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20244720 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010209920 | NHSA |
| Santen Pharmaceutical Co., Ltd. | 国药准字HJ20170378 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010278986 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010281567 | NHSA |
| 成都普什制药有限公司 | 国药准字H20243167 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010302298 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010303094 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20243358 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010304127 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010381567 | NHSA |
| 成都普什制药有限公司 | 国药准字H20243167 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010402298 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010403094 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010481567 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010503094 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010581567 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010603094 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010681567 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010781567 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010881567 | NHSA |
| 广州大光制药有限公司 | 国药准字H20255055 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020100548 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20263729 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020101438 | NHSA |
| 成都普什制药有限公司 | 国药准字H20258188 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020102298 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20253907 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020102733 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20233191 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020104021 | NHSA |
| 珠海前列药业有限公司 | 国药准字H20253202 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020104929 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20244719 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020109920 | NHSA |
| 成都盛迪医药有限公司 | 国药准字H20234117 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020180435 | NHSA |
| 郑州维先医药科技有限公司 | 国药准字H20253919 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020185259 | NHSA |
| 江苏福邦药业有限公司 | 国药准字H20263729 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020201438 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20253907 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020202733 | NHSA |
| 成都盛迪医药有限公司 | 国药准字H20234117 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020280435 | NHSA |
| 成都盛迪医药有限公司 | 国药准字H20234117 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020380435 | NHSA |
| 成都盛迪医药有限公司 | 国药准字H20234117 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020480435 | NHSA |
| 山东华铂凯盛生物科技有限公司 | 国药准字H20266157 | 3%(5ml∶150mg) | Not stated by source | XS01XAD324G010010183034 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 5 filings and 4 distinct first applicants.
Import re-registration 2 · Generic 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Santen Pharmaceutical Co. Ltd.;Santen Pharmaceutical Co. Ltd. Noto Plant | JYHZ2600215 | Import re-registration | 2026/09/03 | Not stated by source | CDE |
| Santen Pharmaceutical Co. Ltd.;Santen Pharmaceutical Co. Ltd. Noto Plant | JYHZ2600214 | Import re-registration | 2026/09/03 | Not stated by source | CDE |
| 修正药业集团长春高新制药有限公司 | CYHS2601847 | Generic | 2026/07/31 | Not stated by source | CDE |
| 湖北康正药业有限公司 | CYHS2601139 | Generic | 2026/05/14 | Not stated by source | CDE |
| 四川好医生攀西药业有限责任公司;合肥华威药业有限公司 | CYHS2600543 | Generic | 2026/02/26 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 修正药业集团长春高新制药有限公司 | CYHS2601847 | Generic | 2026/07/31 | Not stated by source | CDE |
| 湖北康正药业有限公司 | CYHS2601139 | Generic | 2026/05/14 | Not stated by source | CDE |
| 四川好医生攀西药业有限责任公司;合肥华威药业有限公司 | CYHS2600543 | Generic | 2026/02/26 | Not stated by source | CDE |
API registrations
Non-component matches: 14 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 地夸磷索钠 | YAMASA CORPORATION | Y20240001320 | A | Exact ingredient | 2026/10/21 | CDE |
| 地夸磷索钠 | 扬州市三药制药有限公司 | Y20240001036 | A | Exact ingredient | 2026/04/01 | CDE |
| 地夸磷索钠 | 浙江海翔药业股份有限公司 | Y20240000710 | A | Exact ingredient | 2026/05/20 | CDE |
| 地夸磷索钠 | 扬州市三药制药有限公司 | Y20230001112 | I | Exact ingredient | 2024/09/25 | CDE |
| 地夸磷索钠 | 浙江华纳药业有限公司 | Y20230000950 | A | Exact ingredient | 2026/05/20 | CDE |
| 地夸磷索钠 | 湖南华纳大药厂手性药物有限公司 | Y20230000327 | A | Exact ingredient | 2026/06/02 | CDE |
| 地夸磷索钠 | 广东先强药业有限公司 | Y20220000671 | A | Exact ingredient | 2025/02/07 | CDE |
| 地夸磷索钠 | 常州红太阳药业有限公司 | Y20220000502 | A | Exact ingredient | 2024/06/21 | CDE |
| 地夸磷索钠 | 福建南方制药股份有限公司 | Y20220000228 | A | Exact ingredient | 2024/12/31 | CDE |
| 地夸磷索钠 | CKD Bio Corporation | Y20210000722 | A | Exact ingredient | 2023/09/07 | CDE |
| 地夸磷索钠 | 苏州第四制药厂有限公司 | Y20210000612 | A | Exact ingredient | 2023/06/21 | CDE |
| 地夸磷索钠 | Kyongbo Pharmaceutical Co., Ltd. | Y20210000404 | A | Exact ingredient | 2023/07/28 | CDE |
| 地夸磷索钠 | 扬子江药业集团江苏海慈生物药业有限公司 | Y20200001400 | A | Exact ingredient | 2026/05/20 | CDE |
| 地夸磷索钠 | 齐鲁制药有限公司 | Y20200001210 | A | Exact ingredient | 2023/06/30 | CDE |
| 地夸磷索钠 | 广东先强药业有限公司 | Y20200000651 | A | Exact ingredient | 2023/03/24 | CDE |
| 地夸磷索钠 | 成都新越医药有限公司 | Y20200000550 | A | Exact ingredient | 2023/03/24 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03No longer listed under review
海南斯达制药有限公司
CYHS2501887
Fact date: 2026/11/03 · Site observation date: 2026/11/03
Accepted: 2025/05/27
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/09/03Accepted
Santen Pharmaceutical Co. Ltd.;Santen Pharmaceutical Co. Ltd. Noto Plant
JYHZ2600215
Fact date: 2026/09/03 · Site observation date: 2026/10/22
View source ↗ -
2026/09/03Accepted
Santen Pharmaceutical Co. Ltd.;Santen Pharmaceutical Co. Ltd. Noto Plant
JYHZ2600214
Fact date: 2026/09/03 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Diquafosol Sodium Eye Drops
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy